pharmaphorum6d
Novo Nordisk once-weekly insulin clears first phase 3 test
Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
California Made a Big Bet on Producing Its Own Insulin, But There’s No ‘Date Certain’ for Delivery
During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...
Yahoo Finance7d
Insulin Pens Market Report 2024: Segments, Share, Regulatory, Reimbursement and Forecasts to 2036 Featuring Novo Nordisk AS, Eli Lilly and Co, Sanofi
Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.